English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background No herpes zoster (HZ) vaccine for immunosuppressed individuals is currently available. GSK’s candidate HZ vaccine containing recombinant varicella zoster virus glycoprotein E (gE) subunit and AS01B Adjuvant System (HZ/su) showed &amp;gt;90% efficacy for HZ prevention in immunocompetent adults aged ≥50 years. The HZ incidence in individuals with solid tumors (ST) receiving immunosuppressive chemotherapy (chemo) is estimated as 3–4 times higher than in the overall US population (3.2/1000 person-years). We present HZ/su immunogenicity and safety in ST adults aged ≥18 years. Methods In this phase II/III, observer-blind, multicenter study (NCT01798056), ST adults received 2 doses of HZ/su or placebo intramuscularly 1–2 months apart and were randomized 4:4:1:1 to receive a first dose 8–30 days (D) pre-chemo (HZ/su – HZ/su-PreC group, placebo – Pl-PreC) or on chemo start (±1 D) (HZ/su-OnC, Pl-OnC). Vaccine response rates (VRRs) and geometric means (GMs)/means were evaluated for gE humoral immune and gE-specific CD4+ cell-mediated immune (CMI) responses 1 month (M2) and 12 months (M13) post-dose 2. Solicited adverse events (AEs) were recorded for 7 D and unsolicited and medically-attended AEs (MAEs) for 30 D post each dose. Potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) were recorded until study end. Results 185 subjects (65 HZ/su-PreC, 78 Pl-PreC, 22 HZ/su-OnC, 20 Pl-OnC) were included in the according-to-protocol (ATP) cohort for humoral immunogenicity and 58 (27 HZ/su-PreC, 31 Pl-PreC) in the ATP sub-cohort for CMI. The most common ST were breast tumors (54% HZ/su, 49% placebo), followed by colorectal, lung, then other. Humoral and CMI VRRs were higher in HZ/su than Pl groups at M2 and M13. GM concentration (GMC) was highest at M2 in HZ/su-PreC. M13 GMCs were similar in the HZ/su-PreC and HZ/su-OnC groups (Table 1). The frequency of local solicited AEs was higher in HZ/su than Pl groups (Table 2); that of general solicited, unsolicited AEs, MAEs and SAEs was similar among groups (Table 3). 1 pIMD (Pl-OnC) and 23 fatal SAEs were reported. No SAE was considered vaccine-related by investigators. Conclusion HZ/su was highly immunogenic in ST adults receiving chemo. No safety concerns were raised. Funding GlaxoSmithKline Biologicals SA Disclosures P. Vink, GSK group of companies: Employee, Salary and stock options and stock granted

open forum infectious diseases

Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial